Previous Close | 5.1600 |
Open | 5.1100 |
Bid | 4.8400 x 1400 |
Ask | 4.8500 x 1000 |
Day's Range | 4.8100 - 5.1700 |
52 Week Range | 3.8300 - 19.4600 |
Volume | |
Avg. Volume | 869,651 |
Market Cap | 193.13M |
Beta (5Y Monthly) | 1.38 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.1100 |
Earnings Date | Feb 23, 2022 - Feb 28, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | Jan 20, 2017 |
1y Target Est | 31.67 |
GAITHERSBURG, Md., May 16, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate at the following investor conferences in May 2022: H.C. Wainwright Global Investment ConferenceTuesday, May 24, 20227:00 am Eastern TimeThe session will be webcast and can be accessed by visiting the Events section of the Altimmune website. B. Riley Securities Institutional Investor Conference
The last three months have been tough on Altimmune, Inc. ( NASDAQ:ALT ) shareholders, who have seen the share price...
Multiple clinical trial data readouts expected in Q3 and Q4 2022GAITHERSBURG, Md., May 12, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the three months ended March 31, 2022 and provided a corporate update. “We continue to advance the development of pemvidutide, our GLP-1/Glucagon dual receptor agonist and look forward to reporting both weight loss and liver fat reduction data from multiple ongoing clini